Skip to content

Mitral Valve in Hypertrophic Cardiomyopathy

Role of Mitral Valve in the Obstruction of Left Ventricular Outflow Tract in Patients With Hypertrophic Cardiomyopathy

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03877731
Enrollment
100
Registered
2019-03-18
Start date
2006-12-01
Completion date
2019-09-01
Last updated
2026-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertrophic Obstructive Cardiomyopathy

Keywords

hypertrophic cardiomyopathy, mitral valve, echocardiography

Brief summary

The purpose of the study is to assess the role of mitral valve apparatus in the development of outflow tract obstruction in patients with hypertrophic cardiomyopathy and to identify the best surgical treatment modality to relieve outflow tract obstruction in such patients

Detailed description

It is well-known that mitral valve plays an important role in the development of left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. In order to further investigate this phenomenon, the following study aims to compare mitral valve geometry indices, as assessed by transthoracic echocardiography, two- and three-dimentional transesophageal echocardiography and mitral valve quantification analysis, and papillary musles' function, as assessed by 2D speckle tracking imaging, in patients with hypertrophic obstructive cardiomyopathy, patients with arterial hypertension and left ventricular hypertrophy and people without structural heart disease. This will provide information on the geometric characteristics of mitral valve that predispose to the development of obstruction. Futhermore, patients with hypertrophic obstructive cardiomyopathy that are eligible for the surgical relief of obstruction will be randomised into four groups according to the modality of intervention. These groups are as follows: 1) isolated extended septal myectomy; 2) extended septal myectomy + edge to edge mitral valve repair; 3) extended septal myectomy + posterior lealfet sliding plasty; 4) extended septal myectomy + secondary chordae transection. After surgery, said indices will be reassessed and the degree of outflow tract obstruction relief noted, in order to elicit which geometrical changes are produced by each type of intervention. Patients will be followed long-term, up to 5 years, in order to define whether the addition of the intervention on mitral valve helps abolish the residual gradient more effectively, and whether it translates into any survival benefit.

Interventions

PROCEDUREisolated septal myectomy
PROCEDUREseptal myectomy + edge-to-edge mitral valve repair
PROCEDUREseptal myectomy + posterior leaflet sliding plasty
PROCEDUREseptal myectomy + secondary chordae transection

Sponsors

Tomsk National Research Medical Center of the Russian Academy of Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Age \>18 years * Signed informed consent to participate in the study * For patients with hypertrophic cardiomyopathy only: resting or latent peak left ventricular outflow tract gradient \>50 mmHg, NYHA class III-IV * For patients with arterial hypertension only: hystory of arterial pressure increase \>140/90 mmHg, increased left vantricular wall thickness (\>10 mm) and myocardial mass indexed to BSA (\>95 g/m2 for women and \>115 g/m2 for men), as assessed by 2D transthoracic echocardiography

Exclusion criteria

* Age \< 18 years * Persistent form of atrial fibrillation * Intrinsic mitral or aortic valve disease * Coronary artery disease * Reduced left ventricular ejection fraction * For control group only: presence of any structural heart disease

Design outcomes

Primary

MeasureTime frameDescription
Event-free survival5 yearspatients' survival without hospital admissions due to the recurring sympthoms

Secondary

MeasureTime frameDescription
Residual left vetricular outflow tract gradient5 yearsleft ventricular outflow tract gradient measured by continuous doppler from 5-chamber apical view
Mitral regurgitation5 yearsdegree of mitral regurgitation assessed by color doppler, regurgitant volume measured using PISA method
Papillary muscles' funcion5 yearspapillary muscles' strain and strain rate assessed by 2D speckle tracking imaging
Mitral valve geometry10 daysindices of mitral valve geometry assessed by 2D transthoracic and transesophageal echocardiography and mitral valve quantification analysis

Countries

Russia

Contacts

PRINCIPAL_INVESTIGATORElena Pavlyukova, MD, PhD

Cardiology Research Institute, Tomsk NRMC

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 27, 2026